Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 30:175:8-18.
doi: 10.1016/j.pediatrneurol.2025.10.023. Online ahead of print.

Longitudinal Characterization of Males With X-Linked Creatine Transporter Deficiency: Final Results of a Multiyear Observational Study

Affiliations
Free article

Longitudinal Characterization of Males With X-Linked Creatine Transporter Deficiency: Final Results of a Multiyear Observational Study

Judith S Miller et al. Pediatr Neurol. .
Free article

Abstract

Background: The purpose of the Vigilan observational study (ClinicalTrials.gov, NCT02931682) was to prospectively assess the natural history and developmental course of creatine transporter deficiency (CTD).

Methods: Males with CTD aged 6 months to 65 years were evaluated at 6-month intervals for up to 4 years. Evaluations included neurodevelopmental assessments of intellectual functioning, adaptive functioning, and challenging behaviors and the onset and progression of medical comorbidities.

Results: Fifty participants (median age, 7.6 years) were enrolled. The predominant CTD phenotype consisted of significant intellectual disabilities and limited skill development over time. Most participants had a history of febrile or nonfebrile seizures, gastrointestinal symptoms, and growth failure. All participants learned how to walk, 78% developed at least some verbal speech, and 34% communicated using phrases or sentences. Norm-referenced neurodevelopment assessments indicated declining standardized scores over time; however, absolute scores (i.e., age equivalent person ability scores) indicated that developmental gains were slower than average, particularly among older participants. Between-person differences in neurodevelopmental skills as a function of age did not match within-person change, suggesting a cohort effect.

Conclusions: In this cohort, CTD was associated with significant and persistent intellectual disability. The use of absolute metrics from neurodevelopmental tests (e.g., person ability scores) allowed for the quantification of slow, but present, skill development.

Keywords: Cerebral creatine deficiency syndromes; Creatine transporter deficiency; Intellectual disabilities; SLC6A8.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Judith S. Miller has a consultation agreement with Ultragenyx. Susan Blair, Tricia Cimms, Michelle Xu, Lin Zhang, Linda Rees, and Melanie Brandabur are or were employees and stockholders of Ultragenyx Pharmaceutical Inc. at the time this research was conducted. Elizabeth M. Berry-Kravis has received funding from Acadia, Alcobra, AMO, Asuragen, Avexis, Biogen, BioMarin, Cydan, Engrail, Erydel, Fulcrum, GeneTx, GW, Healx, Ionis, Jaguar, Kisbee, Lumos, Marinus, Mazhi, Moment Biosciences, Neuren, Neurogene, Neurotrope, Novartis, Orphazyme/Kempharm/Zevra, Ovid, PTC Therapeutics, Retrophin, Roche, Seaside Therapeutics, Taysha, Tetra, Ultragenyx Pharmaceutical Inc., Yamo, Zynerba, and Vtesse/Sucampo/Mallinckrodt Pharmaceuticals to consult on trial design or perform clinical or laboratory validation trials in genetic neurodevelopmental or neurodegenerative disorders, all of which is directed to RUMC in support of rare disease programs. Dr Berry-Kravis receives no personal funds and RUMC has no relevant financial interest in any of the commercial entities listed. Aleksandra Bruchey was an employee of and stockholder in Lumos Pharma, Inc. at the time this research was conducted. Kim M. Cecil is a consultant for Myrtelle, Inc. Nicola Longo has participated in clinical trials and advisory boards for BioMarin, PTC Therapeutics, Sanofi, and Ultragenyx Pharmaceutical Inc. Forbes D. Porter has a Cooperative Research Agreement between NICHD and Lumos and Ultragenyx Pharmaceutical Inc. Susan Waisbren is a consultant for Ultragenyx Pharmaceutical Inc. Cristan Farmer receives royalties for the ABC. Simona Bianconi, Anna W. Byars, Maxine Covello, Laura S. Cubit, Tanvi Das, Natacha Akshoomoff, Irina Anselm, Bruce A. Barshop, Lindsey Becker, Amanda E. Bennett, Leandra N. Berry, Eva Mamak, Saadet Mercimek-Andrews, Claire Michalak, Samar Rahhal, Gail A. Spiridigliozzi, Caitlin Stone, Nancy R. Sullivan, V. Reid Sutton, Rebecca P. Thomas, Manisha Udhnani, and Audrey Thurm have no conflicts to disclose.

Associated data

LinkOut - more resources